Ovid Therapeutics Inc. SEC Filings

Federated Hermes, Inc. filed Amendment No. 1 to a Schedule 13G reporting shared beneficial ownership of 7,737,166 shares of Ovid Therapeutics common stock, representing 4.15% of the class. The filing lists Federated Hermes, the Voting Shares Irrevocable Trust and named trustees, and includes joint‑filing and power‑of‑attorney exhibits. The filing states the named parties expressly disclaim beneficial ownership of securities held by Managed Funds in accordance with Rule 13d‑4.

Ovid Therapeutics Inc. is changing its finance leadership while keeping continuity. The company and Jeffrey Rona, its Chief Business and Financial Officer and principal financial and accounting officer, mutually agreed to his transition from these roles effective July 6, 2026. The board appointed Charles Carter, previously Senior Vice President of Finance and Financial Planning, as Chief Financial Officer, principal financial officer, principal accounting officer and secretary from the same date. The company states that Rona’s departure is not due to any disagreement over accounting, controls, operations or policies.

Carter will receive a $460,000 annual base salary, a target bonus equal to 35% of salary, and 50,000 restricted stock units vesting in two equal annual installments starting July 6, 2027, plus an additional cash bonus opportunity of $75,000. Rona’s separation agreement provides 12 months of base salary, a prorated 2026 bonus, up to 12 months of COBRA benefits, and post-termination non-solicitation covenants. He will serve as a consultant through December 31, 2027, earning a one-time cash retainer and hourly consulting fees, with his existing equity awards continuing to vest during the consulting period.

Ovid Therapeutics Inc. director Anna Greka received a grant of stock options covering 130,000 shares of common stock. The options have an exercise price of $2.26 per share and expire on June 14, 2036.

According to the grant terms, the 130,000 underlying shares vest in 36 equal monthly installments starting on July 15, 2026, contingent on her continued service with the company through each vesting date. This is a compensation-related award rather than an open-market purchase or sale.

Ovid Therapeutics Inc. director Anna Greka filed a Form 3, which is an initial statement of beneficial ownership for insiders. In this excerpt, no common stock or derivative transactions are reported, and the transaction summary shows zero buys, sells, exercises, gifts, or tax withholdings.

Ovid Therapeutics Inc. reported the results of its annual stockholder meeting held on June 10, 2026. Of 173,037,131 common shares outstanding as of April 15, 2026, 130,958,928 shares, or 75.7%, were represented, providing a valid quorum.

Stockholders elected Jeremy M. Levin to a three-year term on the board of directors, with 87,219,707 votes for, 8,528,008 withheld, and 35,211,213 broker non-votes. They also approved, on an advisory basis, the compensation of named executive officers.

In addition, stockholders ratified the selection of KPMG LLP as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2026, with 130,845,667 votes for, 32,505 against, and 80,756 abstentions.

Ovid Therapeutics Inc. appointed Anna Greka, M.D., Ph.D. to its Board of Directors as a Class III director, effective June 15, 2026. Her term will run until the company’s 2029 annual meeting of stockholders, at which point she would be eligible for re-election.

With her appointment, the Board will expand to seven directors. Dr. Greka will serve on the Compensation Committee and the Science and Technology Committee. She is a Professor of Medicine at Harvard Medical School and holds multiple leadership roles at the Broad Institute, bringing deep scientific and biotech advisory experience.

As a non-employee director, Dr. Greka will receive compensation under Ovid’s standard non-employee director compensation policy and has entered into the company’s standard indemnification agreement. The company states there are no related-party relationships or arrangements requiring disclosure under Regulation S-K Item 404(a).

Ovid Therapeutics ownership filing by Point72 group reports shared holdings of 1,903,943 common shares (including warrants) representing 1.3% of the outstanding stock. The statement, dated as of the close of business on March 31, 2026, attributes shared voting and dispositive power to Point72 Asset Management, Point72 Capital Advisors and Steven A. Cohen for the reported position.

The filing states the 1.3% figure is calculated on an aggregate base of 151,028,955 shares outstanding, which combines 131,874,634 shares reported as of March 16, 2026 and 19,154,321 shares issued in a private placement on March 17, 2026, and assumes exercise of the reported warrants.

Ovid Therapeutics ownership filing reports that Eventide Asset Management, LLC and related filers disclose a 12,773,577-share position in Ovid's common stock, representing 7.3% of outstanding shares as of March 31, 2026. The filing states Eventide holds these shares as investment adviser to the Eventide Healthcare & Life Sciences Fund.

The statement is filed on behalf of Eventide, Finny Kuruvilla, M.D., Ph.D., and Robin C. John and includes the Rule 13d-4 disclaimer that the individual filers disclaim beneficial ownership. The filing is a passive ownership disclosure under Schedule 13G.

Ovid Therapeutics (Common Stock) Schedule 13G reports that Sirenia Capital Management LP and Alex Silverstein together beneficially hold 18,031,333 shares (including shares issuable on warrants) representing 9.9% of the class, calculated on a 151,028,955 share base. The filing states 8,552,333 shares are issuable upon exercise of reported warrants but such exercises are limited by a 9.99% blocker, so the reporting persons cannot currently exercise all warrants to reach the full issuable amount.